Roche just continues to send message about Illumina's offer.
After sending its message to Illumina shareholders, the company immediately released a statement in regard to the offer. The statement somewhat repeated the information that was mentioned in the letter to Illumina shareholders.
The company emphasized that it would consider negotiation as long as Illumina is willing to do so. At this present time, based on Roche's information, Illumina has "refused to enter into negotiations" with the company. As a result, the proposed offer is given based on the publicly available information.
If you are not familiar with the subject, Roche originally offered to acquire Illumina for $44.5 a share. The offer was then raised to $51 per share in March. This represented a 88% premium of Illumina's closing stock price on Dec 21, 2011 which was when the rumor about the acquisition started. Since then, the company has yet to made any progress in the acquisition.
Illumina annual shareholder meetings will occur on April 18, 2012.
After sending its message to Illumina shareholders, the company immediately released a statement in regard to the offer. The statement somewhat repeated the information that was mentioned in the letter to Illumina shareholders.
The company emphasized that it would consider negotiation as long as Illumina is willing to do so. At this present time, based on Roche's information, Illumina has "refused to enter into negotiations" with the company. As a result, the proposed offer is given based on the publicly available information.
If you are not familiar with the subject, Roche originally offered to acquire Illumina for $44.5 a share. The offer was then raised to $51 per share in March. This represented a 88% premium of Illumina's closing stock price on Dec 21, 2011 which was when the rumor about the acquisition started. Since then, the company has yet to made any progress in the acquisition.
Illumina annual shareholder meetings will occur on April 18, 2012.
No comments:
Post a Comment